When a well owned stock that investors simply think ‘can’t go down’ experiences some less positive news flow such was the case with CSL around plasma collection volumes, it’s easy to see why the stock falls which was the case with CSL during 2020. However, the first 6 months or this year has been kinder and they’ve experienced a strong but not spectacular recovery.
MM remains long and bullish CSL initially targeting another 15% upside
Add To Hit List
